PMID- 21272133
OWN - NLM
STAT- MEDLINE
DCOM- 20110607
LR  - 20121115
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 16
IP  - 2
DP  - 2011 Feb
TI  - Triptolide attenuates renal interstitial fibrosis in rats with unilateral 
      ureteral obstruction.
PG  - 200-10
LID - 10.1111/j.1440-1797.2010.01359.x [doi]
AB  - AIM: Extracts of Tripterygium wilfordii Hook F. have been used to treat 
      glomerulonephritis for more than 30 years in China. Most of the anti-inflammatory 
      and immunosuppressive activities of these extracts can be attributed to 
      triptolide (Trip). The present study was to investigate the effect of Trip on 
      renal interstitial fibrosis in a model of unilateral ureteral obstruction (UUO). 
      METHODS: UUO or sham-operated rats were randomly assigned to receive 
      mycophenolate mofetil (MMF), Trip or vehicle and were killed on days 7 and 14 
      after UUO or sham operation. Kidney specimens were fixed for immunohistochemistry 
      for myofibroblasts (alpha-smooth muscle actin, alpha-SMA), macrophages (ED-1), monocyte 
      chemoattractant protein-1 (MCP-1) and osteopontin. Interstitial collagen 
      deposition and amounts of transforming growth factor-beta1 (TGF-beta1) were determined 
      by Sirius red staining and enzyme-linked immunosorbent assay, respectively. The 
      mRNA expression of TGF-beta1, connective tissue growth factor (CTGF), MCP-1 and 
      osteopontin were measured by real-time polymerase chain reaction analysis. 
      RESULTS: The scores for the density of alpha-SMA- and ED-1-positive cells, the 
      staining of MCP-1 and osteopontin, interstitial collagen deposition and amounts 
      of TGF-beta1 were significantly reduced by MMF or Trip. MMF or Trip significantly 
      reduced the mRNA expression of TGF-beta1, CTGF, MCP-1 and osteopontin. CONCLUSION: 
      Trip significantly attenuated tubulointerstitial fibrosis in a rat UUO model and 
      the effect of Trip on renal fibrosis was similar to that of MMF. Trip may be 
      useful as a potential candidate in the treatment of renal fibrosis.
CI  - (c) 2010 The Authors. Nephrology (c) 2010 Asian Pacific Society of Nephrology.
FAU - Yuan, Xiao-Peng
AU  - Yuan XP
AD  - Organ Transplant Centre, First Affiliated Hospital, Sun Yat-sen University, 
      Guangzhou, China.
FAU - He, Xiao-Shun
AU  - He XS
FAU - Wang, Chang-Xi
AU  - Wang CX
FAU - Liu, Long-Shan
AU  - Liu LS
FAU - Fu, Qian
AU  - Fu Q
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Actins)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Diterpenes)
RN  - 0 (Epoxy Compounds)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Phenanthrenes)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (smooth muscle actin, rat)
RN  - 106441-73-0 (Osteopontin)
RN  - 139568-91-5 (Connective Tissue Growth Factor)
RN  - 19ALD1S53J (triptolide)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Actins/metabolism
MH  - Analysis of Variance
MH  - Animals
MH  - Chemokine CCL2/metabolism
MH  - Collagen/drug effects
MH  - Connective Tissue Growth Factor/metabolism
MH  - Diterpenes/pharmacology/*therapeutic use
MH  - Epoxy Compounds/pharmacology/therapeutic use
MH  - Fibrosis/etiology/prevention & control
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kidney/metabolism/*pathology
MH  - Macrophage Activation/drug effects
MH  - Male
MH  - Osteopontin/metabolism
MH  - Phenanthrenes/pharmacology/*therapeutic use
MH  - RNA, Messenger/drug effects/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Transforming Growth Factor beta1/metabolism
MH  - Ureteral Obstruction/*complications
EDAT- 2011/01/29 06:00
MHDA- 2011/06/08 06:00
CRDT- 2011/01/29 06:00
PHST- 2011/01/29 06:00 [entrez]
PHST- 2011/01/29 06:00 [pubmed]
PHST- 2011/06/08 06:00 [medline]
AID - 10.1111/j.1440-1797.2010.01359.x [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2011 Feb;16(2):200-10. doi: 
      10.1111/j.1440-1797.2010.01359.x.